The global Sarcoma Drugs market size was valued at US$ 903 million in 2020 and is anticipated to grow at a CAGR of 9.5% during forecast period 2021 to 2030.
Sarcomas are rare tumors of connective tissue affecting any part of the body such as nerves, tendons, bones, muscle, fat, and skin. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, STS accounts for approximately 87.0% of all sarcoma cases, while malignant bone sarcomas represent close 13.0% of all cases. Globally, the annual incidence rate of STS is 2-3 per 100,000 people. Risk factors include genetic mutation such as inherited defects in the APC gene, TP53 gene, and RB1 gene, damaged lymph system, chemical exposure, and radiation.
In 2017, 12,715 new diagnoses and 5,070 deaths due to STS were reported in the U.S. Bone sarcomas accounted for 3,373 new cases and 1,649 deaths in 2017. The lifetime risk of developing sarcoma is 0.4%. Approximately 45.0% of bone sarcomas and 21.0% of STS are diagnosed in people in the age group of 0-35 years.
Currently, chemotherapy and targeted therapy are the only approved treatments for sarcoma. Several immuno-oncology agents are also under investigation. Recent approvals of chemotherapy drugs such as Eisai’s Halaven and Johnson & Johnson’s Yondelis are based on superior efficacy compared to previously available anthracycline-based treatment regimens. Targeted therapy is anticipated to command the majority shares in the market by 2023, owing to the surging adoption of novel therapeutics and superior efficacy.
Sarcoma treatment landscape has changed dramatically in the last few years with the introduction of targeted therapies. As one of the first molecular targeted drugs approved for solid tumors, Gleevec’s approval as the first-line therapy for GIST, a major sarcoma sub-type in 2002, changed the treatment paradigm for GIST. Following Gleevec, other tyrosine kinase inhibitors (TKIs) have been approved for GISTs such as Sutent and Stivarga, and Votrient for non-GIST soft tissue sarcomas. In addition to TKIs, Lartruvo, the monoclonal antibody that targets platelet-derived growth factor receptor (PDGFR), was shown to extend overall survival of STS patients and was approved in 2016 in the U.S. as a breakthrough therapy. For bone sarcomas, new drugs are limited to Xgeva, a receptor activator of nuclear factor B ligand (RANKL) inhibitor.
Current research in sarcoma focuses on using novel treatments such as targeted therapy, immunotherapy, and combination regimens. Bristol-Myers Squibb’s Opdivo + Yervoy combination is being investigated in a Phase II trial for patients with previously treated metastatic sarcoma. Development of immuno-oncology agents for sarcoma treatment is estimated to target major unmet needs, including disease recurrence, improving progression-free survival, overcoming tumor resistance, and maintaining the quality of life.
Role of checkpoint inhibitors (PD-1/PD-L1) in STS is under evaluation in multiple Phase I/II trials. These treatments in conjunction with standard therapies are poised to provide patients with safer and effective treatment options. Merck is investigating its PD-1 inhibitor Keytruda as monotherapy and in combination with Incyte’s IDO1 inhibitor Epacadostat in patients with advanced STS and bone sarcomas.
Currently, out of 45 drugs in the clinical pipeline, 12 molecular targeted drugs are in development for the treatment of STS and bone sarcoma. Cancer vaccines and gene therapy are also generating interest as a potential treatment for STS. Several other small molecules and monoclonal antibodies are in active development in Phase I and II trials.
The U.S. dominated the sarcoma drugs market with more than 35.0% share in 2020 and is projected to maintain the leading position in 2023. Multiple product launches during the forecast period, increased adoption of novel therapeutics, and the presence of key manufacturers in the U.S. are some of the factors responsible for its dominance.
Novartis, Eli Lilly, Amgen, Pfizer, Johnson & Johnson, Eisai, and Bayer. Late-CStage, ytRx, Tracon Pharma, Blueprint Medicines, Arog Pharmaceuticals, Advenchen Laboratories, and Karyopharm
Treatment Type Outlook
The Sarcoma Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Sarcoma Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Sarcoma Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Sarcoma Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Sarcoma Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Sarcoma Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Sarcoma Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Sarcoma Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Sarcoma Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Sarcoma Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Sarcoma Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Sarcoma Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Sarcoma Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Sarcoma Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Sarcoma Drugs market. These factors have benefited the growth of the global market for Sarcoma Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Sarcoma Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Sarcoma Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Pediatric Wheelchair Market (By Product Type: Manual, Electric; By Frame Type: Rigid, Foldable; By Application: Homecare, Hospital) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Immunotherapy Drugs Market (By Drug Type: Monoclonal Antibodies, Immunomodulators; By Indication: Infectious Diseases, Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
MRI Motion Tracking Systems Market (By Type: Optical Tracking Systems, Software; By Product: Marker, Marker-less) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
5G In Healthcare Market (By Component: Hardwar, Services; By Application: Remote Patient Monitoring; Connected Medical Devices; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Surgical Scissors Market (By Type: Disposable, Reusable; By Application: Cardiology, Orthopedics, Gastroenterology, Dermatology, Neurology; By Material; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...